美國15州發現45例猴痘病例 白宮再訂購50萬劑疫苗
格隆匯6月11日丨據海外網,美國衛生與公衆服務部10日證實,美國白宮再訂購50萬劑疫苗,以應對猴痘疫情。目前,美國已發現45例猴痘確診病例。 美國衛生與公衆服務部助理部長奧康奈爾10日在新聞發佈會上表示,訂購的這批液態冷凍天花疫苗對猴痘病毒有效,預計將於今年晚些時候交付。他還稱,另有30萬劑疫苗預計將在未來幾個星期抵美。 美國疾病控制與預防中心主任瓦倫斯基當天表示,在美國15個州已發現45例猴痘確診病例,幾乎與2003年美國暴發猴痘疫情時的數字相同。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.